Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

ProMIS Neurosciences Inc (PMN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ProMIS Neurosciences's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.890 +0.050    +2.72%
- Closed. Currency in USD ( Disclaimer )
Pre Market
1.800
-0.090
-4.762%
- Real-time Data
Type:  Equity
Market:  United States
  • Volume: 4,424
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.720 - 1.920
ProMIS Neurosciences 1.890 +0.050 +2.72%

ProMIS Neurosciences Inc Company Profile

 
Get an in-depth profile of ProMIS Neurosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

7

Equity Type

ORD

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Contact Information

Address 1920 Yonge Street Suite 200
Toronto, M4S 3E2
Canada
Phone 416 847 6898
Fax 416 847 6899

Top Executives

Name Age Since Title
Eugene Williams 64 2015 Co-Founder & Chairman
Neil R. Cashman 71 2004 Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
Neil K. Warma 61 2021 President, Interim CEO, Principal Executive Officer & Director
Patrick D. Kirwin 67 2015 Independent Director
Sharon Cohen - 2018 Member of Scientific Advisory Board
Michael J. Higgins 62 - Member of Business Advisory Board
William W. Wyman 86 2014 Independent Director
Cheryl Wellington - 2022 Member of Scientific Advisory Board
William C. Mobley - 2017 Member of Scientific Advisory Board
Timothy G. Rothwell 73 2019 Member of Business Advisory Board
Andre Strydom - 2019 Member of Scientific Advisory Board
Nigel Burns - - Member of Business Advisory Board
Charles Warren Olanow - 2019 Member of Scientific Advisory Board
Michelle L. Hastings - - Member of Scientific Advisory Board
Guy A. Rouleau - 2022 Member of Scientific Advisory Board
Joshua Mandel-Brehm 40 2021 Independent Director
Carsten Korth - 2022 Member of Scientific Advisory Board
Madge K. Shafmaster 65 2021 Lead Independent Director
Alain Dagher - 2022 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PMN Comments

Write your thoughts about ProMIS Neurosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email